Neogen (NEOG)
Nasdaq Market Closed
Neogen Corporation is a food safety and animal safety company that develops, manufactures, and markets diagnostic tests, biosecurity products, veterinary instruments, and related solutions. Headquartered in Lansing, Michigan, the company serves customers across agriculture, food production, animal health, and public health markets. Its products are used by food processors, feed manufacturers, livestock producers, veterinarians, laboratories, and regulatory or quality-control professionals.
In food safety, Neogen provides testing and monitoring tools designed to help detect hazards or unwanted substances in food and animal feed. Its diagnostics address issues such as foodborne pathogens, spoilage organisms, allergens, natural toxins, sanitation concerns, and prohibited animal by-products. These products support quality assurance programs and help customers reduce contamination risks, comply with standards, and protect consumer health.
In animal safety, the company offers a wide range of products for veterinary and livestock applications. These include instruments, pharmaceuticals, vaccines, topical treatments, parasiticides, cleaners, disinfectants, insect and rodent control products, and diagnostic tools. Neogen also provides genomics testing services that help livestock producers and breeders make decisions related to animal health, productivity, and genetic traits.
Neogen’s business sits at the intersection of food supply chain integrity, animal care, and agricultural productivity. Its demand drivers include global protein consumption, regulatory scrutiny of food safety, disease prevention in animal populations, and the need for efficient testing across complex supply chains. The company is distinctive for combining diagnostics, biosecurity, and animal genomics under a single safety-focused platform.
Last updated
- Market Cap
- 1.92B
- P/E
- —
- P/FCF
- 314.07
- P/S
- 2.2
- Enterprise Value
- 2.55B
- Sector
- Health Care
- Industry
- In Vitro and In Vivo Diagnostic Substances
- Address
- 620 LESHER PLACE, LANSING, MI, 48912
NEOG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neogen Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation - NEOG
NEOG DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Neogen Corporation Investors to Secure Counsel Before Important September 16 Deadline in Securities Class Action – NEOG
NEOG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neogen Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Neogen Corporation - NEOG
NEOG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neogen Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Neogen Corporation and Encourages Investors to Contact the Firm
NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation - NEOG
DEADLINE ALERT for NEOG, RXST, RMHIX, FI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
NEOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Neogen Corporation - NEOG
NEOG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neogen Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEOG DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Neogen Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – NEOG
NEOG 周一截止日期:獲評為頂尖、業界領先的律師事務所 ROSEN,呼籲損失超過 10 萬美元的 Neogen Corporation 投資人,在證券集體訴訟的重要截止日前尋求法律意見 – NEOG
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm
Deadline Alert: Neogen Corporation (NEOG) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
NEOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Neogen Corporation - NEOG
ROSEN, A LONGSTANDING FIRM, Encourages Neogen Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEOG
DEADLINE ALERT for NEOG, RXST, RMHIX, FI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 16, 2025 in Neogen Corporation Lawsuit – NEOG
NEOG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neogen Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 1.92B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 2.55B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.91
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 2.2
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 32.29
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 2.93
- EPS
- -2.8
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 314.07
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 27.58
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 6.11M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -28.96%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -18.12%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.38
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.09
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.97
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.11
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.67M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 8.81
Income Statement
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Revenue | 211.2M | 224.69M | 209.19M | 225.46M | 221M |
| Gross profit | 99M | 106.68M | 94.97M | 92.86M | 110.3M |
| Operating income | -3.3M | -5.38M | -16.09M | -611.19M | 5.4M |
| EBITDA | 25.62M | 23.55M | 12.96M | 16.98M | 34.75M |
| Net income | -17M | -15.92M | 36.34M | -612.2M | -10.9M |
| Basic EPS | -0.08 | -0.07 | 0.17 | -2.82 | -0.05 |
| Diluted EPS | -0.08 | -0.07 | 0.17 | -2.82 | -0.05 |
Balance Sheet
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total assets | 3.36B | 3.36B | 3.38B | 3.44B | 4.04B |
| Total liabilities | 1.26B | 1.26B | 1.26B | 1.37B | 1.38B |
| Total equity | 2.1B | 2.1B | 2.12B | 2.07B | 2.66B |
| Cash & equivalents | 159.9M | 145.34M | 138.88M | 129M | 127.71M |
| Current assets | 590M | 574.58M | 524.06M | 576.9M | 551.71M |
| Current liabilities | 144.2M | 137.94M | 146.21M | 167.4M | 141.2M |
Cash Flow
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating cash flow | 22.7M | 19.44M | 10.85M | 16.54M | 19.46M |
| Investing cash flow | -11.56M | -11.67M | 97.73M | -15.93M | -32.48M |
| Financing cash flow | 744K | -451K | -99.39M | -2.11M | 930K |
| Change in cash | 14.56M | 6.46M | 9.88M | 1.3M | -12.52M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — NEOGEN CORP | View Filing | |
| edgar index | SD — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Rocklin Amy M | View Filing | |
| form 4 | Form 4 — Rocklin Amy M | View Filing | |
| form 4 | Form 4 — Rocklin Amy M | View Filing | |
| edgar index | SCHEDULE 13G/A — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Moylan John Patrick | View Filing | |
| form 4 | Form 4 — Moylan John Patrick | View Filing | |
| form 4 | Form 4 — Moylan John Patrick | View Filing | |
| form 4 | Form 4 — Stacey Jennifer Evans | View Filing | |
| form 4 | Form 4 — Stacey Jennifer Evans | View Filing | |
| edgar index | SCHEDULE 13G — NEOGEN CORP | View Filing | |
| edgar index | 8-K — NEOGEN CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — NEOGEN CORP | View Filing | |
| edgar index | 8-K — NEOGEN CORP | View Filing | |
| edgar index | 10-Q — NEOGEN CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — NEOGEN CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Nassif Mikheal | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Nassif Mikheal | View Filing | |
| edgar index | 4/A — NEOGEN CORP | View Filing | |
| edgar index | 3 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Nassif Mikheal | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Nassif Mikheal | View Filing | |
| edgar index | 8-K — NEOGEN CORP | View Filing | |
| edgar index | 10-Q — NEOGEN CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Ranalli Tamara A. | View Filing | |
| form 4 | Form 4 — Ranalli Tamara A. | View Filing | |
| form 4 | Form 4 — Ranalli Tamara A. | View Filing | |
| form 4 | Form 4 — Ranalli Tamara A. | View Filing | |
| form 4 | Form 4 — Ranalli Tamara A. | View Filing | |
| edgar index | SCHEDULE 13G/A — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Naemura David H. | View Filing | |
| form 4 | Form 4 — Naemura David H. | View Filing | |
| form 4 | Form 4 — Naemura David H. | View Filing | |
| edgar index | SCHEDULE 13G/A — NEOGEN CORP | View Filing | |
| edgar index | 3/A — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| form 3 | Form 3 — Nassif Mikheal | View Filing | |
| form 3 | Form 3 — Nassif Mikheal | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 3 — NEOGEN CORP | View Filing | |
| form 4 | Form 4 — Riggsbee Richard Bryan | View Filing | |
| form 4 | Form 4 — Riggsbee Richard Bryan | View Filing | |
| form 4 | Form 4 — Nassif Mikheal | View Filing | |
| edgar index | 8-K — NEOGEN CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 3 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing | |
| edgar index | 4 — NEOGEN CORP | View Filing |